Janux Therapeutics, Inc. (JANX) income statement
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3040% below fair value
$10.08−0.21 (-2.04%)
Close on Nov 20, 2026Market cap $616.26MP/E –Yield –
Janux Therapeutics, Inc. financial ratios
See a number that looks wrong?